The role of circadian rhythm on the pharmacokinetic of methotrexate in streptozotocin-induced diabetes mellitus rats

Abstract Chronopharmacokinetic studies have been conducted both in animals and humans. Anticancer agents are of great interest due to their narrow therapeutic range and large pharmacokinetic variability. It was reported that the pharmacokinetics of MTX showed a circadian rhythm in rats and humans. Since diabetes-induced physiological changes can affect pharmacokinetics of drugs, it was reported that MTX blood concentration in diabetic rats was higher than that of the control groups. The present study was designed to elucidate whether these diabetes-induced changes in pharmacokinetics occurred during the day and thus administered MTX at four different times in streptozotocin-induced diabetes mellitus (SIDM) rats. Blood samples were drawn at 5, 15, 30, and 60 min after IV infusion of MTX in both the SIDM and control groups. Control and SIDM Area under the concentration – time curve (AUC) values showed a significant circadian rhythm with a peak located in mid-dark phase at 14:00. Clearance values were significantly low at 14:00 in the diabetic group when compared to other periods and the control group. The MTX AUC was increased when treatment with dexamethasone was given to suppress the endogenous production of corticosterone in both control and SIDM rats. These results suggest that the extent of MTX pharmacokinetics varies with the time of day in the SIDM rats and these variations might be related to changes in corticosterone concentrations.

[1]  J. Radziuk,et al.  Endogenous Glucose Production in Type 2 Diabetes: Basal and Postprandial. Role of Diurnal Rhythms , 2004, Journal of Investigative Medicine.

[2]  R. Schmidt,et al.  Experimental Rat Models of Types 1 and 2 Diabetes Differ in Sympathetic Neuroaxonal Dystrophy , 2004, Journal of neuropathology and experimental neurology.

[3]  R. Goyal,et al.  Anti‐diabetic activity of Zingiber officinale in streptozotocin‐induced type I diabetic rats , 2004, The Journal of pharmacy and pharmacology.

[4]  Tomoko Takahashi,et al.  Enhanced activity of serum and urinary hyaluronidases in streptozotocin-induced diabetic Wistar and GK rats. , 2003, Glycobiology.

[5]  A. Ramanan,et al.  Use of methotrexate in juvenile idiopathic arthritis , 2003, Archives of disease in childhood.

[6]  A. Prémaud,et al.  An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. , 2002, Toxicology and applied pharmacology.

[7]  J. Radziuk,et al.  Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution , 2002, Diabetologia.

[8]  O. Fardel,et al.  Up‐regulation of multidrug resistance‐associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone , 1999, FEBS letters.

[9]  Y. Jung,et al.  Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. , 1998, Research Communications in Molecular Pathology and Pharmacology.

[10]  So H. Kim,et al.  Pharmacokinetics of a new carbapenem, DA‐1131, after intravenous administration to rats with alloxan‐induced diabetes mellitus , 1998, Biopharmaceutics & drug disposition.

[11]  S. Cheema-Dhadli,et al.  Physiological disposal of the potential alkali load in diet of the rat: steps to achieve acid-base balance. , 1998, American journal of physiology. Renal physiology.

[12]  J. M. Park,et al.  Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. , 1996, Research communications in molecular pathology and pharmacology.

[13]  P. Gwilt,et al.  The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in Humans , 1991, Clinical pharmacokinetics.

[14]  G. Koren,et al.  Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. , 1990, American journal of diseases of children.

[15]  T. Hasegawa,et al.  Effect of diabetes on disposition and renal handling of cefazolin in rats. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Feely,et al.  Clinical Pharmacokinetics and Endocrine Disorders , 1987, Clinical pharmacokinetics.

[17]  M. Terrissol,et al.  Chronotoxicity of methotrexate in mice after intraperitoneal administration. , 1987, Chronobiologia.

[18]  F. Lévi,et al.  Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. , 1982, European journal of cancer & clinical oncology.

[19]  J. Arendt,et al.  The effect of abolition of the endogenous corticosteroid rhythm on the circadian variation in methotrexate toxicity in the rat , 2004, Cancer Chemotherapy and Pharmacology.

[20]  G. Ferrazzini,et al.  Diurnal variation of methotrexate disposition in children with acute leukaemia , 2004, European Journal of Clinical Pharmacology.

[21]  G. Bjarnason.  Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. , 1995, In Vivo.

[22]  T. Cachero,et al.  Circadian rhythms of plasma corticosterone at different times after induction of diabetes. Responses to corticoadrenal stimulation in light and dark phases. , 1993, Life sciences.

[23]  G. Koren,et al.  Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. , 1992, Chronobiology international.

[24]  B. Lange,et al.  Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? , 1989, The American journal of pediatric hematology/oncology.

[25]  F. Balis,et al.  Central nervous system pharmacology of antileukemic drugs. , 1989, The American journal of pediatric hematology/oncology.